Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.

Abstract

Age-dependent decline of the anti-tumour efficacy of local IL-2 immunotherapy and chemoimmunotherapy utilizing human recombinant interleukin 2 and cyclophosphamide was investigated in B10 mice bearing syngeneic MC-induced sarcoma. Repeated peritumoral injections of rIL-2 substantially inhibited growth of transplantable MC-induced sarcomas in syngeneic young adult mice whereas no effect was observed in the aged mice. Chemoimmunotherapy of the MC-induced sarcomas in the young adult and in the aged mice treated with cyclophosphamide plus rIL-2 revealed that subthreshold doses of CY were capable of significantly potentiating the immunotherapeutic effect of rIL-2 in young adult mice but not in the aged mice.

Statistics

010002000'96'98'00'02'04'06'08'10'12'14'16
Citations per Year

269 Citations

Semantic Scholar estimates that this publication has 269 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{mov1989ChemoimmunotherapyOM, title={Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.}, author={Jana {\vS}{\'i}mov{\'a} and Jan Buben{\'i}k and Nikolai N. Voitenok and E. J. Gren}, journal={Folia biologica}, year={1989}, volume={35 3}, pages={137-42} }